Senores Pharmaceuticals Ltd

- The management discussed a significant CAPEX plan of over INR 200 crores for the next year focusing on expansion and new facilities. - There was mention of usage of IPO proceeds, specifically INR 107 crores set aside for injectable production facility CAPEX, which will start from Q1 of next year and complete in 18-24 months. - There is no explicit mention of any new or future fundraising plans through debt or equity in the Q3 FY25 earnings call transcript. - The company plans to keep updating the investor community on any incremental updates, which may include future fundraising if pursued. - For further inquiries, investors are encouraged to get in touch with the management or the investor relations advisors.

- Next year's planned CAPEX is firmly more than INR 200 crores, currently on the drawing board. - A greenfield site in India is being scouted to cater to mid-tier emerging markets beyond the Ratnatris site. - Injectable plant CAPEX: groundwork started, actual CAPEX begins Q1 next year, expected completion within 18-24 months; located at existing oral solid site with supporting infrastructure. - Setting up backward integration for APIs primarily in India to improve cost competitiveness and supply security. - Regulated market facility expected to commence this quarter to backward integrate key products for both CDMO/CMO and own products. - Ongoing evaluation for inorganic growth through product acquisitions.

- FY25 Q4 expected to be very strong, with full-year revenue projected between INR 410-440 crores. - FY26 revenue anticipated to grow over 50%-60%, targeting INR 670-700 crores, driven mainly by CDMO/CMO and own product portfolio. - CDMO/CMO revenue expected around $25-$30 million in FY26, with significant product launches ahead (15-17 in current quarter). - Emerging markets showing strong potential with over 530 products under registration for pipeline growth. - Own product portfolio to sustain strong growth with addition of new products annually (51 pipeline products could add $700-$800 million opportunity over 3 years). - Utilization in India plants at 65%-70%, US plants currently 50%, expected to rise to 60%-65% in FY26. - PAT growth expected to outpace top-line growth, potentially doubling in FY26 compared to FY25.

- Strong growth expected: FY25 Q4 anticipated to be very strong with total revenue between INR 410-440 crores. - FY26 revenue growth projected at 50%-60%+ with bottom line (PAT) expected to nearly double compared to FY25. - EBITDA margin expected to improve to higher single digits next year (FY26), increasing to higher teens by FY27-28. - Emerging markets currently break-even at operating level; EBITDA margins targeted at 15%-18% at optimum level. - CDMO/CMO revenue expected to grow significantly, reaching $25-30 million in FY26. - Own product portfolio growth continues, with 27-28 products contributing approx. 30%-35% of portfolio near optimum market share. - New product launches (69 pipeline products over 3 years) can create an additional opportunity of $700-800 million. - Overall, Senores aims for strong sustained growth in revenue, margins, and profits driven by regulated markets, CDMO expansions, and emerging markets.

- Senores has a strong and expanding order book driven by both CDMO/CMO contracts and own products in regulated markets. - The CDMO/CMO vertical currently has 21 commercial products with a pipeline of 69 products expected to launch progressively. - Around 15-17 CDMO/CMO products are targeted for commercialization in Q1 of FY26. - They expect CDMO/CMO revenue for FY26 to be around $25 million to $30 million. - The own product portfolio consists of 22+ products, with 5 more launches planned in Q4 FY25. - The company has 51 own products in the pipeline, aiming to add more products annually. - Product registrations in emerging markets stand at 537, with 237 already approved, supporting future commercialization. - The robust pipeline and order book across segments underpin company growth guidance with top-line expected to grow 50%-60% in FY26.